BIOASTER poster “Microfluidic chip for bacterial biofilm formation and analysis” presented at Lab-on-a-Chip and Microfluidics Europe 2024 Conference, https://lnkd.in/dHaRN--Z has been awarded as Best Poster Awards - third position- Sponsored by Lab-on-a-Chip Journal, Royal Society of Chemistry (RSC) Want to know more?: contact Gabriele Pitingolo
BIOASTER
Recherche en biotechnologie
Disrupting Healthcare - De-risking Innovation - Transforming Technologies
À propos
BIOASTER Technology Research Institute (TRI) is working to develop an unique technological and innovative model to support the latest challenges in microbiology, in particular to : -Fight antimicrobials resistance. -Improve vaccines safety and efficacy. -Quickly diagnose infections at patient bedside. -take full advantage to human and animal microbiota. In order to overcome technological bottlenecks and explore new avenues, BIOASTER is leading collaborative projects that bring together academics, start-ups, SMEs and industrial groups around key thematic and technology units. Each project strives on academic research excellence and is undertaken by a team of high-level experts and engineers, which benefits from state-of-the-art equipment, technological infrastructures. BIOASTER, an independent non-profit organization, is one of 8 French TRIs created in 2012 on the initiative of the French Government through the “Investments for the Future” program. The two historical founders are Lyonbiopôle (a biocluster, the one-stop shop for healthcare innovation in Rhône-Alpes, France) and the Institut Pasteur in Paris. They were joined from the beginning by the CNRS, the INSERM, the CEA, Mérieux Institute, Danone Nutricia Research and Sanofi Pasteur -and newly joined by bioMérieux- to create a unique Technology Institute dedicated to infectious diseases and microbiology in health. The Institute benefits from the support of Lyon Métropole and the Region Auvergne Rhône Alpes and the dynamism of a group of 40 SMEs in the Lyon and Paris regions. Located in Lyon and Paris, BIOASTER has more than 100 employees including 80 world-class scientists and engineers originating from 16 different countries. More information on www.bioaster.org
- Site web
-
http://www.bioaster.org
Lien externe pour BIOASTER
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 51-200 employés
- Siège social
- Lyon
- Type
- Non lucratif
- Fondée en
- 2012
- Domaines
- Biotechnology, Infectious diseases, Microbiota, Vaccines, Antimicrobials, Diagnostic et Microbiology
Lieux
-
Principal
Obtenir l’itinéraire
40 avenue Tony Garnier
69007 Lyon, FR
Employés chez BIOASTER
-
Pawel Tulinski, PhD
Microbiology Maestro 🔬| Driving Innovation in Microbiology 🧫 and Unlocking the Secrets of Microbes 🦠
-
Philippe Archinard
Deputy CEO . Innovation and Scientific Partnerships at Institut Mérieux
-
Hortion Lyvia
-
Christophe Védrine
Head of Bioassays, Microsystems and Optical engineering unit at BIOASTER
Nouvelles
-
Xavier Morge BIOASTER intervient à la table ronde de l'événement #healtechaccelerationsummit BIOTECHFINANCES " "LES TECHNO-ACCÉLÉRATIONS : HALLUCINATIONS OU RÉALITÉS TANGIBLES" #innovation
-
-
BIOASTER, membre de France BioLead, participe à la #JNBB2024! #innovation #Bioproduction !
Journée Nationale de la #Bioproduction de #Biomédicaments : découvrez tous les événements digitaux qui se tiendront le 5 juillet dans toute la France 🇫🇷 ! #JNBB2024
-
-
BIOASTER is proud to announce that it has obtained Olink Proteomics certification, becoming one of only 3 laboratories in France to offer this new proteomics approach. Thanks to PEA (Proximity Extension Assay) technology, the targeted panels (Target 48, 96 and Flex) allow you to identify between 15 and 92 protein biomarkers of interests from a very small quantity of human and mouse samples (1-2µl). Olink complements our existing mass spectrometry-based methods for proteomics analysis. With our multi-OMICS technologies in #proteomics #transcriptomics, #genomics and #metabolomics, we can support you in biomarker discovery, improving bioproduction processes and elucidating mechanisms of actions of drugs or vaccines. Feel free to contact us for additional information! Mallory Poncelet Jean-Marc Monneuse Hayat HAGE Adrien Saliou #proteomics #olink #biomarkers #drugs #moA #bioproduction #qPCR #targetedpanel
-
-
Le 27 juin prochain, #healtechaccelerationsummit notre CEO Xavier Morge BIOASTER participera à une table ronde "LES TECHNO-ACCÉLÉRATIONS : HALLUCINATIONS OU RÉALITÉS TANGIBLES". Le programme est ici : https://lnkd.in/ghuR29UU BIOTECHFINANCES
-
-
Don't miss the talk of Dr Ilia Belotserkovsky BIOASTER “Set-up of Immunocompetent Mid-throughput Gut-on-a-Chip Model to Study Host - Microbiota Interaction”. #microbiota #gutonchip June 18-20 Prague
🔬🧫🧬 Impairment of epithelial barrier and induction of inflammation in the intestine underline a variety of pathologies in humans including inflammatory bowel diseases (IBD) as well as metabolic and neurological diseases. 👩⚕️ Intestinal microbiota and the host immune system are the key players determining intestinal homeostasis and inflammation. 🧬 Novel bio-therapies such as pre- / pro- / and post-biotics are extensively developed to aid maintaining and restoring the impaired balance between intestinal microbiota and host immune response. Their selection and validation is a complex process involving in-vitro and in-vivo models, while the former is lacking the complexity of the physiological system, the latter often fails reflecting the effect in humans. 👨🔬 The development of new pertinent and easy-to-use models is therefore needed. 🧫 The current Gut-on-a-Chip model recapitulates the key features of intestinal inflammation and enables an easy screen of novel (bio) therapeutics in a mid-throughput manner. Moreover, the use of donor derived immune cells and fecal material paves the way towards personalized medicine approach. 🧬 Future development will be focused on testing the effect of matched fecal microbiota and PBMC from IBD patients compared to healthy donors. Switching to biopsy derived intestinal epithelium from patients will render this model more physiologically relevant for testing new interventions aiming IBD. 🎤 To find out more, meet Ilia Belotserkovsky from BIOASTER France at the 17th IPC2024 in Prague, 18-21 June 2024 and... Hit the bell 🔔🔔🔔 to stay tuned on to International Scientific Conference on #Probiotics, #Prebiotics, #Gut #Microbiota and #Health - #IPC2024 and get updated on probiotic, prebiotic #science and #microbiota #research.
-
-
Dr Lucia Pagani BIOASTER will give a talk at the ADTCA (Advancing Data Technologies to Corner AMR) 2024, an online, International Matchmaking Symposium by AMR Insights. The talk will be on the 21st of June, and the title is: Novel Artificial Intelligence developments in AMR. https://lnkd.in/eWYYCxzW #AMR #IA #innovation
Advancing Data Technologies to Corner AMR (ADTCA) 2024 - AMR Insights
https://www.amr-insights.eu
-
It's today ! #ADAYBIOASTERBIOASTER "The race against Antimicrobial resistance" Matmut Stadium Gerland 150 people & more than 70 different companies will attend this one day "in real life" conference! #AMR #innovation #microbiology #SOLVEAMR ICTA PharmaLex CYNBIOSE ONLYLYON Lyonbiopôle Auvergne-Rhône-Alpes #France2030
-
-
Cyril Guyard CSO BIOASTER interviendra lors de la conférence internationale « La vaccination comme principal outil de prévention des épidémies et du cancer » organisée dans le cadre de l’exposition « Épidémies – Prendre soin du vivant » (Musée des Confluences) et des Fêtes consulaires 2024, qui se tiendra au @CIRC IARC - International Agency for Research on Cancer / World Health Organization le jeudi 13 juin 2024, 25 avenue Tony Garnier - 69007 Lyon. Inscriptions: https://lnkd.in/dKzbEMBu
Consulats en Fête : Conférence «La vaccination comme outil de prévention des épidémies et du cancer»
events.iarc.who.int
-
Today we have the pleasure to welcome the BioBAY team https://lnkd.in/eq7mZWQR BioBAY delegation: Jianguo YIN, Chairman, Lijuan GU, General Manager, Jianxin PAN, Postdoctoral Researcher, Yifan SHI, Senior Specialist The BioBAY delegation will be accompanied by Bruno Versaevel Head of HITS (Healthcare Innovation, Technology & Society) Institute & Professor of Economics emlyon business school BIOASTER Régis Villet Alexandre Moulin
资本市场丨必扬医药：完成数千万PreA 轮融资，加速推进眼科与肿瘤管线IND注册申报研究
biobay.com.cn